Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease
Haemophilia · 2024
DOI: 10.1111/hae.15079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Geoffrey Z L Kuppens und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Ne…. Hauptthemen laut MEDLINE: von Willebrand Factor, Factor VIII, von Willebrand Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients with von Willebrand disease (VWD) require administration of von Willebrand factor (VWF) concentrates peri‐operatively. Concerns about FVIII accumulation after repetitive injections of a 1:1 ratio VWF/FVIII clotting factor concentrate (CFC) led this study to explore the recovery and FVIII accumulation over time.
Methods
This monocentre study examined patients with VWD receiving perioperative 1:1 ratio CFC infusions. CFC dosing was based on body weight and endogenous VWF/FVIII activity. FVIII and VWF activity was monitored at T0 (baseline), T1 (15 min postinfusion), and trough levels at T2‐T6 (24‐120 h).
Results
We included 125 patients, undergoing 125 procedures (63 major surgeries, 62 minor), with a median of two CFC infusions (IQR 1–3). With a mean administered dose of 35.7 IU/kg CFC, recovery rates of FVIII and VWF were 2.6 IU/dL per IU/kg and 2.4 IU/dL per IU/kg, respectively. Mean FVIII levels at T0 were 62 (SD 51.9), T1: 164 (SD 80.4), T2: 155 (SD 62.8), T3: 162 (SD 59.8), T4: 124 (SD 78.4), and T5: 120 (SD 65.3) IU/dL. Mean VWF activity levels at T0 were 29 (SD 25.0), T1: 133 (SD 43.7), T2: 92 (SD 37.2), and T3: 86 (SD 37.5) IU/dL. Subgroup analysis in 47 patients with more than three infusions, showed no accumulation of mean FVIII levels.
Conclusion
This perioperative study demonstrated excellent FVIII and VWF recovery of a 1:1 ratio VWF product in patients with VWD. Stable FVIII and VWF activity levels were observed after repeated infusions, without accumulation. Most major surgeries required only three CFC infusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
ORCID-Profile: Geoffrey Z L Kuppens, Kathelijn Fischer, Karin P M van Galen, Idske C L Kremer Hovinga, Lize F D van Vulpen, Roger E G Schutgens
Zitieren
APA
Kuppens, G. Z. L., Fischer, K., van Galen, K. P. M., van Beers, E. J., Van der Valk, P. R., Kremer Hovinga, I. C. L., van Vulpen, L. F. D., & Schutgens, R. E. G. (2024). Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease. Haemophilia. https://doi.org/10.1111/hae.15079
Vancouver
Kuppens GZL, Fischer K, van Galen KPM, van Beers EJ, Van der Valk PR, Kremer Hovinga ICL, et al. Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease. Haemophilia. 2024. doi:10.1111/hae.15079
BibTeX
@article{Kuppens2024,
author = {Kuppens, Geoffrey Z L and Fischer, Kathelijn and van Galen, Karin P M and van Beers, Eduard J and Van der Valk, Paul R and Kremer Hovinga, Idske C L and van Vulpen, Lize F D and Schutgens, Roger E G},
title = {Efficacy of a 1:1 ratio VWF/FVIII concentrate in patients with von Willebrand disease},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15079}
}
EUVIMED